Multi-Agonism

3 articles in this topic.

Complete Guides

Multi-Agonism's Ceiling: Do More Receptors Mean More?

Dual and triple GLP-1/GIP/glucagon agonists produce escalating weight loss, but each added receptor brings diminishing gains and rising side effects.

18 min read|Mar 20, 2026

All Articles

Multi-Agonism

More Receptors, More Weight Loss? The Multi-Agonist Science

Multi-agonist peptides target GLP-1, GIP, and glucagon receptors at once. Retatrutide hit 24.2% weight loss in phase 2, the most ever for any drug.

14 min read|Mar 22, 2026

Multi-Agonism

Dual vs Triple Agonist Peptides: Is More Better?

Tirzepatide (dual) and retatrutide (triple) target different receptor combinations. We compare the clinical data on weight loss, side effects, and tradeoffs.

14 min read|Mar 21, 2026